WASHINGTON (Reuters) - Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc's lung drug Spiriva compared with placebo, the U.S. Food and Drug ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

Pfizer and BioNTech said Monday that late-stage trials of its COVID-19 vaccine in children show that the shots were safe and effective in kids aged between 5 and 11. The results mark a key step in ...

Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15. Lyme disease is a bacterial ...

Co announces rates of virologic suppression in patients receiving Pfizer's CCR5 antagonist, maraviroc, compared to efavirenz were 70.6% vs. 73.1% for less than 400 copies/ml and 65.3% vs. 69.3% at ...